Management of Breakthrough Bleeding During Extended Therapy Use With NuvaRing®
NCT ID: NCT00475553
Last Updated: 2009-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
75 participants
INTERVENTIONAL
2006-05-31
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The most common reason for discontinuation of an extended contraception regimen is irregular bleeding. The purpose of this research study is to evaluate the best way to manage this breakthrough spotting and bleeding. Ease of use and acceptability of a flexible regimen of NuvaRing will also be evaluated. A comparison of cyclic mood symptoms, pelvic pain, and headaches will be made between a standard 21/7 regimen and an extended regimen.
The contraceptive ring used in this study contains both an estrogen (ethinyl estradiol) and a progestin (etonogestrel). These are synthetic (man-made) hormones. The amount of ethinyl estrogen released into the bloodstream each day is 120mcg and the amount of etonogestrel is 150mcg. The NuvaRing®, by Organon, is FDA approved for contraception, but is not approved for use in an extended regimen. Therefore its use in this study is considered investigational.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 2
Subject will use the nuvaring and if they developed breakthrough bleeding or spotting for more than 5 days on the 6th day the ring would be removed and would leave it out for 3 full days and reinsert the same ring the next day. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
remove ring if bleeding or spotting occurs more than 5 days
Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
Group 1
Subject is using the nuvaring continuously and it would be changed out monthly. If she develops breakthrough bleeding or spotting she does not remove the ring until it is her time to change it. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
If bleeding does not remove ring
Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
remove ring if bleeding or spotting occurs more than 5 days
Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
If bleeding does not remove ring
Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently utilizing combination estrogen/progestin contraception for a period of at least 2 months or 1 month if previously using a progestin only pill.
Exclusion Criteria
* Anyone who should not be using hormonal contraception due to contraindications
* Anyone who smokes \> 10 cigarettes per day or if 35 years old or older smokes any cigarettes
* Anyone who is taking antiretroviral therapy (due to many drug interactions)
* Women using other estrogen-containing products or herbal products that contain phytoestrogens
* Known or suspected pregnancy, or desiring pregnancy in the next year
Additionally, NuvaRing® should not be used in women who currently have the following conditions:
* Thrombophlebitis
* A past history of deep vein thrombophlebitis or thromboembolic disorders
* Cerebral vascular or coronary artery disease (current or history)
* Valvular heart disease with thrombogenic complications
* Severe hypertension
* Diabetes with vascular involvement
* Headaches with focal neurological symptoms
* Major surgery in patients with prolonged immobilization
* Known or suspected carcinoma of the breast or personal history of breast cancer
* Carcinoma of the endometrium or other known or suspected estrogen dependent neoplasia
* Undiagnosed abnormal genital bleeding
* Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use
* Hepatic tumors (benign or malignant) or active live disease
* Hypersensitivity to any components of NuvaRing®
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Organon
INDUSTRY
Scott and White Hospital & Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Scott and White Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Patricia Sulak, MD
Role: PRINCIPAL_INVESTIGATOR
Scott and White Hospital & Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scott & White Hospital and Clinic
Temple, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
50403
Identifier Type: -
Identifier Source: org_study_id